AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ra Medical Systems to Showcase Pharos, Optimized Dermatology Excimer Laser at Two Upcoming Dermatology Conferences

January 23, 2020 GMT

CARLSBAD, Calif.--(BUSINESS WIRE)--Jan 23, 2020--

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces it will be showcasing its Pharos, Optimized Dermatology Excimer Laser at two upcoming dermatology conferences.

“We are pleased to showcase the Pharos, Optimized excimer laser to the many dermatologists and healthcare providers attending these key industry conferences,” said Andrew Jackson, Ra Medical Systems CFO and Interim CEO. “This next-generation Pharos laser was designed to enhance physician and patient experiences with faster treatment times and extended peak performance. I’m pleased to report that the Pharos, Optimized laser has been received positively in the six months since its commercial introduction.”

About Pharos Excimer Laser

Pharos is a powerful 308 nm ultraviolet-B excimer laser used by physicians as a tool to treat the following chronic skin diseases: psoriasis, vitiligo, atopic dermatitis, and leukoderma. Ra Medical Systems has FDA clearance and CE Mark clearance to market Pharos for use in the treatment of those skin conditions, as well as market clearance in China. Pharos is the only excimer laser to feature integrated adjustable aiming and laser beams to deliver precisely targeted treatments that spare healthy tissue. The laser’s small footprint enables it to fit into any treatment room, saving valuable floor space.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017, the DABRA laser system and single-use DABRA catheter received FDA 510(k) clearance in the U.S. as a device for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Ra Medical’s future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding Ra Medical’s business strategy, including the continued adoption of Pharos, Optimized. Ra Medical’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medical’s products; the results from our clinical trials, which may not support intended indications or may require Ra Medical to conduct additional clinical trials or modify ongoing clinical trials; challenges related to commencement, patient enrollment, completion, an analysis of clinical trials; Ra Medical’s ability to manage operating expenses; Ra Medical’s ability to effectively manage inventory; Ra Medical’s ability to recruit and retain management and key personnel; Ra Medical’s need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medical’s industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medical’s news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical’s business and operating results is contained in Ra Medical’s Annual Report on Form 10-K for the year ended December 31, 2018 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the company through a variety of means, including our website ( www.ramed.com ), our investor relations website ( https://ir.ramed.com/ ), press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200123005176/en/

CONTACT: At the Company:

Jeffrey Kraws

President, Ra Medical Systems

760-496-9008

jkraws@ramed.comInvestors and Media:

LHA Investor Relations

Jody Cain / Kevin McCabe

310-691-7100

jcain@lhai.com/kmccabe@lhai.com

KEYWORD: CALIFORNIA HAWAII UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: GENERAL HEALTH HEALTH MEDICAL DEVICES

SOURCE: Ra Medical Systems, Inc.

Copyright Business Wire 2020.

PUB: 01/23/2020 06:50 AM/DISC: 01/23/2020 06:50 AM

http://www.businesswire.com/news/home/20200123005176/en